Experts concur that event-related oral PrEP probably won’t work for women
Who are trans women acquiring HIV from?
One in seven people offered PrEP in African study start it immediately
Trans women wary of antiretroviral drug and hormone interactions
People with HIV are at risk for liver fibrosis and steatosis
Peripheral artery disease more common in people with HIV with lower CD4 counts
PrEP use in US exceeds 100,000 in Gilead pharmacy survey
Switch from boosted protease inhibitor to dolutegravir reduces lipids in people with HIV at higher risk of heart disease
Boosted darunavir plus lamivudine matches three-drug regimen
What marks out HIV controllers from others?
Why curing HIV may be like curing cancer – and may be as difficult
Can we achieve a complete HIV cure in more patients?
VRC01 antibody can delay but not prevent viral rebound after interruption of early treatment
Long-acting NRTI shows promise for HIV treatment and PrEP
Stillbirth more frequent in women with HIV in UK and Ireland than in general population
US HIV funding decisions on PEPFAR in 2017 will have critical effect on ability to reach 90-90-90 goals
First protease inhibitor combination pill maintains viral suppression
Adolescents with HIV do better in more prosperous African countries, even with treatment
